Clinical Trial To Evaluate ANT-1207 In Subjects With Acne

Clinical Trial To Evaluate Botulinum Neurotoxin Type A (ANT-1207) In Subjects With Acne

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01293552

Enrollment

Registered

2011-02-10

Start date

2011-01-31

Completion date

2012-07-31

Last updated

2013-07-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris

Brief summary

The purpose of this study is to provide evidence of the safety, tolerance, and efficacy of ANT-1207 in the treatment of acne.

Interventions

BIOLOGICALANT-1207

single dose application

BIOLOGICALVehicle

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* diagnosis of moderate to severe facial acne * 15 to 40 papules and pustules, and 5 to 50 open and/or closed comedones * no presence of nodules * female subjects must be not pregnant and non-lactating

Exclusion criteria

* presence of 1 or more nodules * use of topical steroids on the face 4 weeks prior and during the study * use of systemic corticosteroids 6 weeks prior and during the study * topical or systemic acne treatment in the 4 weeks prior to Baseline

Design outcomes

Primary

Measure	Time frame	Description
Efficacy will be assessed by lesion count.	Week 4	inflammatory lesion count (papules, pustules, and nodules) and non-inflammatory lesion count (open and closed comedones)

Secondary

Measure	Time frame
Change from Baseline in Investigator Global Assessment Score	Week 1, 2, 4, 8, and 12
Change from Baseline in Lesion Count	Week 1, 2, 4, 8, 12

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026